Semaglutide Injection: Incorrect Pen In Package
Semaglutide Injection Recall Summary Certain packages of semaglutide injection contain an incorrect pen that does not match the intended dose strength for that package. This packaging error affects semaglutide injection products distributed across Canada. The FDA classified this as a Class II recall, meaning the defect could cause adverse health effects.
- Product
- Semaglutide Injection
- Reason
- Packaging defect
- Classification
- Class II
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2026-08-11
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/a6ec802a-8e34-47d4-b3f0-ee571f578495